Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with Alzheimer's disease agents.

Abstract: Methods and intermediates for the preparation of oligomers containing diastereomerically enriched phosphorothioate linkages are disclosed.

Abstract: This invention describes novel purified and isolated nucleic acid molecules or the fragments thereof, extracted from nematode or arthropod pests or recombinant, which encode P-glycoprotein homologs and regulate resistance to the macrocyclic lactone compounds. The invention further relates to the new P-glycoprotein homolog expression product of these nucleic acids. Also described herein are methods for detecting the gene encoding for resistance to the macrocyclic lactone compounds in nematode or arthropod pests which comprise comparing the nucleic acids extracted from a pest specimen to the nucleic acids encoding for resistance and the nucleic acids encoding for susceptibility to the macrocyclic lactone compounds.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antiarrythmics.

Abstract: The present invention to an isolated DNA which codes for a gene essential for cell wall glucan synthesis of Candida albicans, wherein the gene is referred to as CaKRE9, wherein the sequence of the DNA is as set forth in FIG. 1. The present invention relates to antifungal in vitro and in vivo screening assays for identifying compounds which inhabit the synthesis, assembly and/or regulation of &bgr;1,6-glucan. There is also disclosed an in vitro method for the diagnosis of disease caused by fungal infection in a patient.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antineoplastic agents.

Abstract: The invention relates to an enzyme linked immunosorbent assay (ELISA) method and kit for the rapid determination of metabolic phenotypes for Cytochrome P450 2C19 (CYP 2C19). The kit uses may include but are not limited to, use on a routine basis in a clinical laboratory to determine a Cytochrome P450 2C19 (CYP 2C19) phenotype of an individual; to allow a physician to individualize an individual's treatment with respect to the numerous drugs metabolized by CYP 2C19 based on a phenotypic determination; to predict an individual's susceptibility to carcinogen induced diseases including many cancers, and to screen individuals for a preferred metabolic phenotype in order to determine those individuals with a responsive phenotype for participation in clinical testing.

Abstract: A process is described to provide a protein fraction with high functionality, in particular high gelling, including gelling by the process of cold-set gelation and high solubility properties, and to a process for obtaining same. The process comprises extracting the gelling protein from ground defatted soybean with an alkaline solution. Optionally, the gelling protein is isolated by centrifugation of the alkaline solution to obtain a supernatant comprising the gelling protein, precipitation of the gelling protein from the supernatant, and sedimentation of the so-precipitated gelling protein.

Abstract: The invention features methods for diagnosing subjects at risk for or suffering from a disease or disorder, such as a psychosis. Methods are also provided for selecting a preferred therapy for a particular subject or group of subjects.

Abstract: The present invention relates to a medium for promoting the survival of islet cells, which comprises one or more growth factors in combination with FK506 in amounts having an anti-apoptotic effect on islet cells in a physiologically acceptable culture medium.

Abstract: The present invention provides a novel dominant selectable marker system in yeast that is based on an aminoglycoside, nourseothricin (NST). This compound possesses a powerful antifungal activity against Candida albicans and S. cerevisiae. The invention provides a cognate drug resistance marker for use in gene transformation and disruption experimentation in Candida albicans and Saccharomyces cerevisiae. In particular, the invention presents: 1) direct utility for gene manipulations in both clinically and experimentally relevant strains regardless of genotype and without affecting growth rate, or hyphal formation; and 2) applicability to antifungal drug discovery, including target validation and various forms of drug screening assays.

Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a classical cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for inducing apoptosis in cadherin-expressing cells, such as cancer cells, are also provided.

Abstract: Agents that inhibit the development of cancer and tumor growth are provided. Such agents comprise a classical cadherin CAR sequence HAV within a cyclic peptide ring, and may be used to prevent or treat cancer.

Abstract: The invention features substantially pure NRAGE polypeptides. The invention also features substantially pure nucleic acids encoding these polypeptides. The polypeptides and nucleic acids of the invention are useful for therapeutic and diagnostic purposes, and for drug discovery.

Abstract: The invention features p28 Bap31 polypeptides and nucleic acids. The invention also features methods for modulating apoptosis using these polypeptides and nucleic acids, and methods for identifying apoptosis-modulating compounds.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with analgesics.

Abstract: Revascularization of an ischemic myocardium is achieved through the stimulation of angiogenesis (new blood vessel formation) by causing an injury to the heart via puncturing and traversing the ischemic myocardium from the epicardium to the endocardium simultaneously, at a plurality of spaced apart sites, with a plurality of needles, and simultaneously withdrawing the plurality of needles from the punctured ischemic myocardium; the technique and the device have advantages over the use of lasers for this purpose an additional advantage is that the revascularization can be performed without open chest surgery or conventional sternotomy although it can also be employed in conjunction with these surgical procedures; thus, by way of example, the revascularization can be performed transthoracically; with a t sternotomy, a thoractomy incision or thoracoscopically; the puncturing operation may also be employed in myogenesis of a myocardium by delivery of desired agents to the myocardium through the puncturing needles;

Abstract: Modulating agents for inhibiting an interaction between &agr;-catenin and &bgr;-catenin are provided. The modulating agents comprise one or more of: (a) a &bgr;-catenin HAV motif; (b) a peptide analogue or mimetic of a &bgr;-catenin HAV motif; or (c) an antibody or antigen-binding fragment thereof that specifically binds to a &bgr;-catenin HAV motif. Methods for using such modulating agents for inhibiting cadherin-mediated cell adhesion in a variety of contexts are also provided.

Abstract: The present invention relates to mouse and human cDNAs for a gene family designated Nramp (natural resistance-associated macrophage protein), involved in macrophage function and responsible for the natural resistance to infection with intracellular parasites, and to the isolation of Nramp sequences from other animal sources. The nucleotide sequences of the mouse and human cDNAs are disclosed, as are the amino sequences of the encoded products. The cDNAs can be expressed in expression constructs. These expression constructs and the proteins produced therefrom can be used for a variety of purposes including diagnostic and therapeutic methods.

Abstract: The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with antidepressants.